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Introduction
The American Society of Clinical Oncology (ASCO)
Annual Meeting is a leading educational and scientific
event for oncologists, clinical researchers, academics and
other health care professionals involved in multidisciplinary
cancer care. This year the congress was held in Chicago,
Illinois, from May 31 to June 3. The theme for the 39th
annual meeting was ‘Commitment, care, compassion: hon-
ouring people with cancer’. The goal of the meeting was to
promote communication among cancer related medical
specialities and the exchange of ideas arising from ongoing
advances in oncology. This encompassed the areas of
pathophysiology, diagnosis and management, and included
innovations in therapies. For the first time this year, an oral
presentation session was devoted to pharmacogenomics.
A wide range of translational scientific research relevant to
breast cancer was covered as well as new clinical data
pertinent to breast oncology management.
Gene profiling in translational breast cancer
research
Worldwide, many research groups are concentrating on
breast cancer gene expression and molecular profiling,
and this area was given significant coverage at the ASCO
meeting. The first presentation in the meeting’s plenary
session, given by Lajos Pusztai from the MD Anderson
group, dealt with the predictive nature of profiling in terms
of response to chemotherapy. Their group described the
use of gene expression profiling in predicting complete
pathological response (pCR) to neoadjuvant chemother-
apy with a paclitaxel and anthracycline combination
(abstract #1 [1]). In 21 patients the overall accuracy of
response prediction based on a group of five genes (three
oestrogen sulphotransferases, nuclear factor 1/A, and
histone acetyltransferase) was 81% and the positive pre-
dictive value for pCR was 75%, with an overall specificity
of 93%, although sensitivity fell to 50%.
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Abstract
The annual American Society of Clinical Oncology congress is the largest forum for cancer
professionals in the world, promoting new developments in cancer medicine. A wide spectrum of
subjects relevant to breast cancer research and treatment was covered in this year’s meeting,
including chemotherapy in the neoadjuvant and adjuvant settings, molecular and gene profiling studies,
and use of more conventional prognostic and predictive markers of outcome. This report discusses
some of the highlights in translational and clinical aspects of early breast cancer management
presented at the meeting.
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The group from Baylor College (abstract #32 [1]) pre-
sented their work on gene expression patterns for de novo
and acquired resistance to docetaxel. Twenty-four patients
had paired samples before and after four cycles of doc-
etaxel 100mg/m2. Docetaxel resistance occurred in 54%
of the tumours and 46% were sensitive. Resistant tumours
showed elevated baseline expression of some transcrip-
tional genes and genes involved in repair/synthesis. Doc-
etaxel-sensitive tumours showed higher baseline
expression of mitochondrial proteins related to apoptosis.
After 3 months of docetaxel chemotherapy, both the resis-
tant and the sensitive groups exhibited the ‘resistant’
profile, suggesting that de novo and acquired chemother-
apy resistance have the same or similar genotype. This
work has now been published in detail in the Lancet [2].
The group from Yamato, Japan (abstract #34 [1]), looked
at oligonucleotide microarrays in 20 patients receiving
neoadjuvant chemotherapy with doxyfluoridine 800mg/m2
days 1–14 and docetaxel 60mg/ m2 day 8 every 3 weeks
for four cycles. Out of 76 genes, among the good respon-
ders 15 genes were upregulated, including diubiquitin,
ICAM-3, N-myc, and RNA-helicase, whereas 13 genes
were downregulated.
Clearly, the hope is that molecular profiling in breast
cancer will provide both a prognostic tool, as described
elegantly by van ‘t Veer and coworkers [3] in their seminal
paper published in Nature, and also a tool for predicting
response to different chemotherapeutic agents. Molecular
profiling may also identify groups of genes, which may
provide targets – at a single gene and a pathway level –
for the development of more specific therapeutic mole-
cules.
Neoadjuvant chemotherapy
The neoadjuvant setting in breast cancer provides excel-
lent opportunities as a ‘biomarker discovery laboratory’
(abstract #33 [1]) and a test ground for newer treatment
combinations. A number of abstracts focused on primary
systemic chemotherapy, including the molecular transla-
tional research discussed above. Efforts to identify good
predictive factors for response are well placed because
the outcome measure occurs early and can inform
research on larger trial samples in the adjuvant setting.
The important features of the neoadjuvant presentations
are summarized in Table 1. pCR is highlighted as the most
significant early outcome measure in these studies. We
understand from the work of Chollet and coworkers [4]
that, irrespective of initial prognostic factors in a tumour,
when pCR is achieved this correlates with a disease-free
survival of over 80% at 10 years. The highest pCR seen in
this group of abstracts is that from Limentani
(abstract #131 [1]), with a 36% pCR to docetaxel
60mg/m2 and vinorelbine 45mg/m2 given every 2 weeks
with granulocyte colony-stimulating factor (GCSF)
support, with the addition of herceptin in the HER2-posi-
tive population.
Perhaps the most noteworthy of the neoadjuvant abstracts
is that from Ramirez-Ugalde and coworkers from Mexico
City (abstract #160 [1]). Patients with stable or progres-
sive disease following standard anthracycline-based
neoadjuvant chemotherapy were treated with weekly 5-flu-
orouracil, gemcitabine and dexamethasone during radio-
therapy to the breast (50 Gy with 10 Gy boost). A pCR
rate of 28% was noted, with attainment of minimal residual
disease in a further 23%, making surgery possible in 47
out of 49 patients. This is a truly remarkable achievement
in this group of breast cancer patients selected for their
refractoriness to anthracyclines. Further evaluation of the
combination of chemotherapy and radiotherapy may be
useful in this poor prognosis group.
Early breast cancer: adjuvant chemotherapy
Mamounas presented the updated results of the NSABP-
B28 study, which examined the addition of four cycles of
paclitaxel 225mg/m2 to the standard of four cycles of
doxorubicin and cyclophosphamide (abstract #12 [1]). A
total of 3060 patients were randomized, and the study
now has a median follow up of 64 months. Disease-free
survival shows a relative risk for relapse of 0.83
(P=0.008) in favour of the addition of paclitaxel, although
overall survival did not show the same advantage (relative
risk 0.94, P=0.46). There appeared to be no interaction
of taxanes with oestrogen receptor (ER) positivity,
although a confounding factor may be the concomitant
treatment of ER-positive patients with tamoxifen. There are
at present no significant differences in death rates
between the standard and experimental arm. This is
perhaps because the prognosis of patients in the study is
very good and that at median follow up of 64 months it is
too early to detect any differences. This study supports
the earlier findings of CALGB 9344 [5], which indicated
benefit from the addition of taxanes, although the CALGB
9344 study suggested a definite interaction between ER
status and benefit from taxanes. In ER-negative disease
there are now more studies showing lack of interaction
than studies showing positive interaction [6].
This report reiterates the difference in biology between
hormone receptor (HR) positive and negative disease.
Analysis of relapse and survival in the first 5 years is more
informative for the HR-negative group, in which the major-
ity of events occur within this time frame, rather than for
the HR-positive population, in which events occur more
often after 5 years (abstract #55 [1]). Similarly, the inter-
action of chemotherapy treatments appears to produce
more effect in the HR-negative population within the first
5 years, and in the HR-positive population after this time
[7]. This must be remembered when analyzing adjuvant291
studies that include a high proportion of HR-positive
women (66% in this study).
The National Epirubicin Adjuvant Trial (NEAT) trial
(abstract #13 [1]) was presented by Dr Chris Poole from
the Cancer Research UK Institute and Cancer Trials Unit
in Birmingham. This is the first of the large adjuvant
chemotherapy trials to come from the UK, and shows a
very significant advantage for epirubicin, cyclophos-
phamide, methotrexate and fluorouracil (ECMF)
chemotherapy in terms of both disease-free and overall
survival when compared with standard classical
cyclophosphamide, methotrexate and fluorouracil (CMF)
for six cycles. The study is the most strongly positive of the
very few individual trials that demonstrate an advantage for
anthracycline-based chemotherapy. This advantage is
demonstrated across all stratification groups. The study
has been reported as a preplanned meta-analysis with a
smaller trial run by the Scottish Cancer Therapy Network,
which asked broadly similar questions. The event-driven
analysis was carried out 18 months later than anticipated,
suggesting that the results for patients treated on the
standard CMF arm were considerably better than had
been predicted before the trial started.
The trial has both proved an advantage for the Bonadonna
block-scheduling anthracycline approach [8], and
improved outcomes for breast cancer patients in the UK
by insisting on adherence to the two classical CMF sched-
ules (oral or intravenous cyclophosphamide). Direct com-
parisons in the metastatic setting had already shown
three-weekly CMF to be inferior, and the analysis by
Bonadonna and coworkers of their own original CMF
study [9] showed that less than 85% dose delivery of the
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Table 1
Summary and findings of neoadjuvant chemotherapy trials
Abstract no. Treatment n pCR
1 Paclitaxel weekly and FAC 24 25%
(breast and lymph nodes)
32 Docetaxel 100 mg/m2 q 3 weeks × 4 24 0%
33 Doxorubicin 75 mg/m2 × 3; then docetaxel 40 mg/m2 q week × 6 70 12.5%
34 Doxyfluoridine 800 mg/m2 D1–14; docetaxel 60 mg/m2 D8 q 3 weeks 20 14%
35 Paclitaxel doxorubicin standard or DD × 6 460 ER– 26%
ER+ 8%
37 Paclitaxel + doxorubicin × 4 then CMF × 4 451 23%
80 Epirubicin 120 mg/m2 q 3 weeks ± tamoxifen 211 ER– 23.4%
ER+ 4.6%
83 Vinorelbine 25mg/m2 D1 + 8 and epirubicin 60 mg/m2 D1 versus AC × 6 411 15% both arms
85 TAC × 2: then PR to TAC × 6 (107 patients) 151 19%
<PR to TAC × 4 (24 patients) 26% for clinical 
or vinorelbine and xeloda × 4 (20 patients) responders to TAC
86 Vinorelbine/herceptin 28 29%
cCR+PR 93%
107 Epirubicin 60mg/m2 D1, CDDP 60 mg/m2 D1, xeloda 1000 mg/m2 BD D1–14 48 27%
131 Docetaxel 60 mg/m2 + vinorelbine 45 mg/m2 q 2 weeks + GCSF + herceptin in HER2+ 33 36%
140 Gemcitabine 1 g/m2, epirubicin 90 mg/ m2, paclitaxel 175 mg/m2 q 3 weeks 22 22.7%
143 Docetaxel 100 mg/m2 q 3 weeks × 4 42 10%
160 Anthracycline SD or PD; 5FU 500 mg/m2/w + gemcitabine 100 mg/m2/w 47 28%
+ dexamethasone 16 mg throughout radiotherapy (50 Gy +10 Gy boost) MRD (+pN0) 23%
163 Docetaxel 75 mg/m2 + doxorubicin 50 mg/m2 + cyclophosphamide 37 8%
500 mg/m2 × 4 q 3 weeks
190 Docetaxel 100 mg/m2 q 3 weeks × 6 88 19.8%
CMF, cyclophosphamide, methotrexate and fluorouracil; ER, oestrogen receptor; 5FU, 5-fluorouracil; FAC, 5-fluorouracil, doxorubicin and
cyclophosphamide; GCSF, granulocyte colony-stimulating factor; pCR, complete pathological response; TAC, docetaxel, doxorubicin and
cyclophosphamide; PR, partial response; <PR, less than a partial response; cCR, complete clinical response; CDDP, cisplatin; DD, dose dense;
SD, stable disease; PD, progessive disease; MRD, minimal residual disease; +pNO, pathological node negative.292
classical CMF resulted in inferior outcomes. At ASCO
2002 the group reported that the ECMF regimen is tolera-
ble [10]. This study provided further confirmation of the
benefit from anthracycline-based treatment and shows that,
unlike four cycles of doxorubicin and cyclophosphamide,
which was shown to be equivalent to CMF, the ECMF
block-scheduling is definitely superior. The emergence of
acute myeloid leukaemia/myelodysplastic syndrome in the
fluorouracil, epirubicin and cyclophosphamide (FEC) D1
and 8 studies (the only other studies to show in a ‘stand
alone way’ the superiority of anthracyclines) raises con-
cerns [11]. To date no cases of acute myeloid leukaemia
have been reported in the NEAT and Scottish studies,
although at present follow up is shorter.
Following the recently successful CALGB 9471 adjuvant
study [12], which showed a strongly positive result for
dose dense therapy, it is of considerable interest to see
early reports of piloted adjuvant treatments from this
group. Abstract 46 [1] described an adjuvant phase II
study of dose dense FEC followed by weekly paclitaxel
and docetaxel. This pilot study looked at both feasibility
and efficacy. FEC (500/100/500mg/m2) was adminis-
tered every 2 weeks for six cycles with GCSF support, fol-
lowed by weekly paclitaxel (80mg/m2) and docetaxel
(35mg/m2) for 18 weeks (a total of 30 weeks of treat-
ment). This schedule produced significant toxicity with
grade 3/4 pneumonitis in four out of 44 (9%), requiring
prolonged hospitalization. This complication seemed
wholly attributable to the dose dense FEC. Seventeen
patients proceeded with the second phase of weekly
taxanes for 18 weeks, and after completion of this two out
of 17 patients (11%) developed severe pleural and peri-
cardial effusions, again necessitating hospitalization. This
protocol is not being further developed for high-risk
patients, and may interestingly set a new limit to the
amount of intensification achievable with GCSF support
alone rather than stem cell haematological support.
Fumoleau (abstract #91 [1]) presented data for the
French Adjuvant Study Group (FASG). This was a 7-year
analysis of the benefit/risk ratio of epirubicin in adjuvant
chemotherapy trials (3577 patients). When used at classi-
cal doses up to epirubicin 100mg/m2 per cycle, the
benefit/risk ratio in operable breast cancer remains in
favour of epirubicin-based adjuvant chemotherapy. A
10-year update of the FASG 05 trial (FEC50 versus
FEC100) presented by Bonneterre (abstract #93 [1]),
analyzing benefit/risk ratio after adjuvant chemotherapy in
node-positive early breast cancer patients, confirmed the
advantage at 10 years of FEC100 over FEC50.
Prognostic/predictive markers (conventional)
A number of abstracts were presented on more conven-
tional tumour markers as both predictive and prognostic
factors. The British Columbia Tissue Micro-Array Project
(BCTMAP; abstract #9 [1]) examined the impact of cyclo-
oxygenase (COX)-2, HER2 and aromatase expression in
930 patients with breast cancer enrolled in phase II/III clin-
ical trials. Expression of HER2 and COX-2 but not aro-
matase was associated with poorer breast cancer specific
survival; however, positivity for both COX-2 in addition to
HER2 did not increase the relative risk for death related to
breast cancer when compared with all other groups. The
data were felt to support the likelihood of interactions
between COX-2, HER2 and aromatase pathways.
The Austrian Breast and Colorectal Cancer Study Group
(ABCSG) reported on 512 patients in ABCSG Trial 5
(abstract #10 [1]). Premenopausal HR-positive patients
were randomized between CMF chemotherapy and com-
bined hormonal therapy with tamoxifen and goserelin.
High p27Kip1 expression was observed in 413 patients.
Combination endocrine therapy was superior to CMF in
patients with high p27Kip1 expression but not in low
expressing patients. Adjusted relative risks for relapse and
death after combined endocrine therapy when compared
with CMF were as follows: high p27Kip1 0.52 (95% confi-
dence interval 0.32–0.83; P=0.006) and 0.51 (95% con-
fidence interval 0.21–1.25; P=0.14) for relapse and
death, respectively. In women with low p27Kip1 expres-
sion there was no difference in response for CMF or com-
bined hormone therapy. These results suggest that
p27Kip1 may be a useful marker for selection of patients
for combined endocrine therapy in this premenopausal
group. ER status was shown in neoadjuvant trials to
predict response to neoadjuvant chemotherapy
(abstracts #35 and #80 [1]). ER-negative patients had
higher rates of pCR to chemotherapy. Increased respon-
siveness is also related to Ki67 positivity. This is confirma-
tory evidence to support the hypothesis of interaction
between different tumour biology (ER-positive versus
ER-negative disease) and response to chemotherapy.
Recent clinical data from trials sequencing tamoxifen and
chemotherapy support the use of sequential hormone
therapy after completion of chemotherapy to produce
better outcomes for patients.
Ravdin and coworkers (abstract #55 [1]) looked at the
predictive factor of ER-negative tumours in the adjuvant
setting. They concluded that ER-negative status should
not be used as the sole criteria for deciding on adjuvant
chemotherapy in node-negative patients. This poster pre-
sented some interesting survival curves from diagnosis
comparing the ER-negative group with the ER-positive
one. The prevalence of death from breast cancer rose
quickly in the ER-negative group and peaked at 3 years
with only a small dip at 4 years, before a ‘twin peak’ at
5 years. The ER-positive curve showed a slow increase in
risk for recurrence through time with the two survival
curves crossing at 8.5 years from diagnosis. These sur-
vival curves are of considerable interest and attest to the
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different tumour biology of ER-positive and ER-negative
disease, and to the way in which these two different
types of breast cancer might interact with chemotherapy
treatment.
The group from the MD Anderson Cancer Center
(abstract #56 [1]) reported on the prognostic value of epi-
dermal growth factor receptor expression, and its ability to
add to the prognostic effect of HER2 over-expression. The
Guy’s Group (abstract #144 [1]) with the MRC Cancer
Trials Unit presented their estimates for overall survival
probabilities and probable benefit for adjuvant systemic
therapy (both hormonal and chemotherapy). The predicted
survival at 10 years from this model of a 55-year-old with a
30mm grade 3 tumour with two positive nodes was as
follows: no treatment 38%; chemotherapy alone 47%;
hormonal therapy for ER-positive tumour 64%; and hor-
monal therapy plus chemotherapy 69%. This represents
an improvement in absolute terms of 31% in 10-year sur-
vival, with substantial contributions from both chemother-
apy and hormonal therapy.
Conclusion
The 39th ASCO Annual Meeting showcased many inter-
esting developments in clinical and translational research
that are relevant to breast cancer, allowing dissemination
of useful information to people working in cancer related
medical specialities. Improved understanding of the patho-
genesis of breast cancer, emerging prognostic and pre-
dictive strategies, and developments in clinical data for
therapeutic interventions will significantly influence our
breast cancer practice in the future.
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